

SURVIVAL OF RECTAL CANCER BASED ON STAGE AND TREATMENT OPTIONS

Table 11. Rectal Pooled Analysis: 5-Year Survival by Risk Group and Treatment Method

Risk Group/TN Stage	%					
	S	S + RT	S + CT	RT + bolus CT*	RT + PVI CT	RT + bolus CT†
Overall survival						
Intermediate risk						
T1-2/N1 (n = 355)	41	67	85	83	78	82
T3/N0 (n = 1,060)	65	62	84	76	80	74
Moderately high						
T1-2/N2 (n = 226)	20 (5)	60	43	55	44	77
T3/N1 (n = 887)	40	50	52	61	73	63
T4/N0 (n = 111)	0 (2)	33 (3)	70 (10)	58	80	67
High risk						
T3/N2 (n = 935)	24	22	45	42	46	50
T4/N1 (n = 62)	50 (4)	40 (5)	29 (7)	57	0 (1)	31
T4/N2 (n = 108)	—	0 (9)	25 (4)	29	53	44
Disease-free survival						
Intermediate risk						
T1-2/N1 (n = 355)	29	61	78	78	76	75
T3/N0 (n = 1,058)	51	50	69	63	75	66
Moderately high						
T1-2/N2 (n = 226)	20 (5)	60	36	48	39	66
T3/N1 (n = 881)	24	33	43	51	63	51
T4/N0 (n = 111)	0 (2)	33 (3)	50 (10)	55	70	55
High risk						
T3/N2 (n = 929)	16	18	36	34	30	42
T4/N1 (n = 62)	50 (4)	40 (5)	14 (7)	57	0 (1)	26
T4/N2 (n = 108)	—	0 (9)	25 (4)	26	47	31

NOTE: See Table 1 for method of bolus CT. Data in parentheses indicate number of at-risk patients.
 Abbreviations: S, surgery; RT, radiation; CT, chemotherapy; PVI, protracted venous infusion.
 *North Central Cancer Treatment Group and National Surgical Adjuvant Breast and Bowel Project trials.
 †US Gastrointestinal Intergroup 0114 trial.

Reference: [Gunderson II, et al. / Clin Oncol 2004;22:1785 - 96.](#)

LOCATION OF RECTAL CANCER RELAPSE BASED ON STAGE AND TREATMENT OPTIONS

Table 12. Rectal Pooled Analysis: 5-Year Relapse Rates by Risk Group and Treatment Method

Risk Group/TN Stage	%					
	S	S + RT	S + CT	RT + bolus CT*	RT + PVI CT	RT + bolus CT†
Local relapse						
Intermediate risk						
T1-2/N1 (n = 355)	12	7	5	6	5	6
T3/N0 (n = 1,058)	14	12	11	10	5	8
Moderately high						
T1-2/N2 (n = 226)	40 (5)	10	0	13	11	9
T3/N1 (n = 881)	11	13	17	12	9	10
T4/N0 (n = 111)	NA (2)‡	33 (3)	20 (10)	18	10	11
High risk						
T3/N2 (n = 929)	24	11	15	17	11	15
T4/N1 (n = 62)	50 (4)	0 (5)	43 (7)	0	18	22
T4/N2 (n = 108)	—	NA (9)§	0 (4)	22	33	16
Distant						
Intermediate risk						
T1-2/N1 (n = 355)	41	25	16	14	15	14
T3/N0 (n = 1,058)	34	31	18	20	13	18
Moderately high						
T1-2/N2 (n = 226)	40 (5)	30	57	40	61	28
T3/N1 (n = 881)	60	53	37	35	30	33
T4/N0 (n = 111)	NA (2)‡	67 (3)	20 (10)	27	59	25
High risk						
T3/N2 (n = 929)	59	70	46	53	30	41
T4/N1 (n = 62)	50 (4)	80 (5)	43 (7)	40	36	34
T4/N2 (n = 108)	—	78 (9)	75 (4)	78	22	53

NOTE. See Table 1 for method of bolus chemotherapy (CT). Data in parentheses indicate number of at-risk patients.

Abbreviations: S, surgery; RT, radiation; CT, chemotherapy; PVI, protracted venous infusion; NA, not applicable.

*North Central Cancer Treatment Group and National Surgical Adjuvant Breast and Bowel Project trials.

†US Gastrointestinal Intergroup 0114 trial.

‡Patients had < 2 years of follow-up.

§Patients had < 2 years of follow-up (three local recurrences).

Reference: [Gunderson II, et al. J Clin Oncol 2004;22:1785 - 96.](#)